Design, synthesis and structure-activity relationship of novel semi-synthetic flavonoids as antiproliferative agents

Show simple item record

dc.contributor.author Ragab F.A.
dc.contributor.author Yahya T.A.A.
dc.contributor.author El-Naa M.M.
dc.contributor.author Arafa R.K.
dc.contributor.other Pharmaceutical Chemistry Department
dc.contributor.other Faculty of Pharmacy
dc.contributor.other Cairo University
dc.contributor.other 11562 Cairo
dc.contributor.other Egypt; Medicinal Chemistry Department
dc.contributor.other Faculty of Pharmacy
dc.contributor.other Sana'a University
dc.contributor.other Sana'a
dc.contributor.other Yemen; Pharmacology and Toxicology Department
dc.contributor.other Faculty of Pharmacy
dc.contributor.other October University for Modern Sciences and Arts
dc.contributor.other Egypt
dc.date.accessioned 2020-01-09T20:42:07Z
dc.date.available 2020-01-09T20:42:07Z
dc.date.issued 2014
dc.identifier.issn 2235234
dc.identifier.other https://doi.org/10.1016/j.ejmech.2014.06.007
dc.identifier.other PubMed ID 24937184
dc.identifier.uri https://t.ly/2d3Xk
dc.description Scopus
dc.description.abstract Various flavonoid scaffold based derivatives viz furochalcones (3a-e, 6a-d and 9a-d), furoflavones (10a-d, 11a-d, 12a-d, 18a&b), flavones (21a-d), furoaurones (13a,b, 14a-d and 15a-d) and 7-styrylfurochromones (22a-d and 25a-e) were designed and synthesized. The novel compounds were evaluated for their antiproliferative activity against a panel of 60 cancer cell lines comprising 9 types of tumors. Ten compounds belonging to the major subgroups of flavonoids viz furochalcones (3a, 3d, 6b, 9a and 9b), furoflavones (12a and 12c), furoaurones (15d), styrylfurochromones (25b and 25e) showed very promising activity. These active compounds were also evaluated in vitro as kinase inhibitors against CDK2/cyclin E1, CDK4/cyclin D1 and GSK-3? and the best inhibition was displayed against GSK-3? with the allylfurochalcone derivative 9b exhibiting 80% decrease in GSK-3? catalytic activity. On the other hand, the styrylfurochromone 25e interestingly showed a 13% enhancement of GSK-3? catalytic power and a 12% reduction in CDK4/cyclin D1 activity. Finally, the in vivo anti-tumor activity of 25e was evaluated against breast cancer induced in mice. The results showed a profound anti-tumor effect of 25e that accompanies a significant increase and decrease in the levels of GSK-3? and cyclin D1, respectively. � 2014 Elsevier Masson SAS. All rights reserved. en_US
dc.description.uri https://www.scimagojr.com/journalsearch.php?q=17464&tip=sid&clean=0
dc.language.iso English en_US
dc.publisher Elsevier Masson SAS en_US
dc.relation.ispartofseries European Journal of Medicinal Chemistry
dc.relation.ispartofseries 82
dc.subject Cytotoxicity en_US
dc.subject Furoaurones en_US
dc.subject Furochalcones en_US
dc.subject Furoflavones en_US
dc.subject Furostyrylfurochromones en_US
dc.subject Kinase inhibition en_US
dc.subject 1 (6 hydroxy 4 methoxy 1 benzofuran 5 yl) 3 (2 methoxyphenyl)prop 2 en 1 one en_US
dc.subject 1 (6 hydroxy 4 methoxy 1 benzofuran 5 yl) 3 (substituted)phenylprop 2 en 1 one en_US
dc.subject 1 (7 allyl 6 hydroxy 4 methoxy 1 benzofuran 5 yl) 3 (4 chlorophenyl) prop 2 en 1 one en_US
dc.subject 1 (7 allyl 6 hydroxy 4 methoxy 1 benzofuran 5 yl) 3 (substituted)phenyl prop 2 en 1 one en_US
dc.subject 1 (7 allyl 6 hydroxy 4 methoxybenzofuran 5 yl) 3 (2methoxyphenyl)prop 2 en 1 one en_US
dc.subject 1 (7 bromo 6 hydroxy 4 methoxy 1 benzofuran 5 yl) 3 (2 methoxy phenyl)prop 2 en 1 one en_US
dc.subject 1 (7 bromo 6 hydroxy 4 methoxy 1 benzofuran 5 yl) 3 (4 methoxy phenyl)prop 2 en 1 one en_US
dc.subject 1 (7 bromo 6 hydroxy 4 methoxy 1 benzofuran 5 yl) 3 (chlorophenyl)prop 2 en 1 one en_US
dc.subject 1 (7 bromo 6 hydroxy 4 methoxy 1 benzofuran-5 yl) 3 phenylprop 2 en 1 one en_US
dc.subject 1 (7 bromo 6 hydroxy 4 methoxy 1 benzofuran-5 yl) 3 substituted phenylprop 2 en 1 one en_US
dc.subject 3 (4 methoxy 5 oxo 7 (substituted)phenyl 5h furo[3,2 g]chromen 9 yl)acrylaldehyde en_US
dc.subject 3 (4 methoxy 5 oxo 7 phenyl 5h furo[3,2 g]chromen 9 yl) acrylaldehyde en_US
dc.subject 3 [4 methoxy 7 (4 methoxyphenyl) 5 oxo 5h furo[3,2 g] chromen 9 yl]acryl aldehyde en_US
dc.subject 3 [7 (4 chlorophenyl) 4 methoxy 5 oxo 5h furo[3,2 g] chromen 9 yl]acrylaldehyde en_US
dc.subject 4 methoxy 7 (2 methoxyphenyl) 5h furo[3,2 g]chromen 5 one en_US
dc.subject 4 methoxy 7 (substituted)phenyl furo[3,2 g]chromen 5 one en_US
dc.subject 4,9 dimethoxy 7 [2 (4 dimethylaminophenyl)vinyl] 6 (morpholin 4 ylmethyl) 5h furo [3,2 g]chromen 5 one en_US
dc.subject 9 bromo 4 methoxy 7 (2 methoxyphenyl) 5h furo[3,2 g] chromen 5 one en_US
dc.subject 9 bromo 4 methoxy 7 (4 methoxyphenyl) 5h furo[3,2 g] chromen 5 one en_US
dc.subject 9 bromo 4 methoxy 7 (substituted)phenyl furo[3,2 g]chromen 5 one en_US
dc.subject 9 bromo 4 methoxy 7 phenyl 5h furo[3,2 g]chromen 5 one en_US
dc.subject 9 bromo 7 (4 chlorophenyl) 4 methoxy 5h furo[3,2 g]chromen 5 one en_US
dc.subject antineoplastic agent en_US
dc.subject cyclin D1 en_US
dc.subject cyclin dependent kinase 2 en_US
dc.subject cyclin dependent kinase 4 en_US
dc.subject cyclin E en_US
dc.subject flavonoid en_US
dc.subject glycogen synthase kinase 3beta en_US
dc.subject unclassified drug en_US
dc.subject unindexed drug en_US
dc.subject antineoplastic agent en_US
dc.subject flavonoid en_US
dc.subject animal experiment en_US
dc.subject animal model en_US
dc.subject antineoplastic activity en_US
dc.subject antiproliferative activity en_US
dc.subject article en_US
dc.subject brain cancer en_US
dc.subject breast cancer en_US
dc.subject cancer cell en_US
dc.subject cancer inhibition en_US
dc.subject cancer size en_US
dc.subject colon cancer en_US
dc.subject controlled study en_US
dc.subject drug cytotoxicity en_US
dc.subject drug design en_US
dc.subject drug mechanism en_US
dc.subject drug megadose en_US
dc.subject drug screening en_US
dc.subject drug synthesis en_US
dc.subject Ehrlich ascites tumor en_US
dc.subject enzyme activity en_US
dc.subject enzyme inhibition en_US
dc.subject human en_US
dc.subject human cell en_US
dc.subject kidney cancer en_US
dc.subject leukemia en_US
dc.subject low drug dose en_US
dc.subject lung non small cell cancer en_US
dc.subject melanoma en_US
dc.subject mouse en_US
dc.subject nonhuman en_US
dc.subject prostate cancer en_US
dc.subject protein expression en_US
dc.subject proton nuclear magnetic resonance en_US
dc.subject stereospecificity en_US
dc.subject structure activity relation en_US
dc.subject animal en_US
dc.subject Bagg albino mouse en_US
dc.subject Carcinoma, Ehrlich Tumor en_US
dc.subject cell proliferation en_US
dc.subject chemical structure en_US
dc.subject chemistry en_US
dc.subject dose response en_US
dc.subject drug effects en_US
dc.subject female en_US
dc.subject pathology en_US
dc.subject structure activity relation en_US
dc.subject synthesis en_US
dc.subject tumor cell line en_US
dc.subject Animals en_US
dc.subject Antineoplastic Agents en_US
dc.subject Carcinoma, Ehrlich Tumor en_US
dc.subject Cell Line, Tumor en_US
dc.subject Cell Proliferation en_US
dc.subject Dose-Response Relationship, Drug en_US
dc.subject Drug Design en_US
dc.subject Drug Screening Assays, Antitumor en_US
dc.subject Female en_US
dc.subject Flavonoids en_US
dc.subject Humans en_US
dc.subject Mice en_US
dc.subject Mice, Inbred BALB C en_US
dc.subject Molecular Structure en_US
dc.subject Structure-Activity Relationship en_US
dc.title Design, synthesis and structure-activity relationship of novel semi-synthetic flavonoids as antiproliferative agents en_US
dc.type Article en_US
dcterms.isReferencedBy Aherne, S.A., O'Brien, N.M., Dietary flavonols: Chemistry, food content, and metabolism (2002) Nutrition, 18 (1), pp. 75-81. , DOI 10.1016/S0899-9007(01)00695-5, PII S0899900701006955; Craig, W.J., Health-promoting properties of common herbs (1999) American Journal of Clinical Nutrition, 70 (3 SUPPL.), pp. 491S-499S; Ren, W., Qiao, Z., Wang, H., Zhu, L., Zhang, L., Flavonoids: Promising anticancer agents (2003) Medicinal Research Reviews, 23 (4), pp. 519-534. , DOI 10.1002/med.10033; Lopez-Lazaro, M., Flavonoids as anticancer agents: Structure-activity relationship study (2002) Current Medicinal Chemistry - Anti-Cancer Agents, 2 (6), pp. 691-714. , DOI 10.2174/1568011023353714; So, F.V., Guthrie, N., Chambers, A.F., Carroll, K.K., Inhibition of proliferation of estrogen receptor-positive MCF-7 human breast cancer cells by flavonoids in the presence and absence of excess estrogen (1997) Cancer Letters, 112 (2), pp. 127-133. , DOI 10.1016/S0304-3835(96)04557-0, PII S0304383596045570; Ibrahim, A.-R., Abul-Hajj, Y.J., Aromatase inhibition by flavonoids (1990) Journal of Steroid Biochemistry and Molecular Biology, 37 (2), pp. 257-260. , DOI 10.1016/0960-0760(90)90335-I; Jeong, H.J., Shin, Y.G., Kim, I.H., Pezzuto, J.M., Inhibition of aromatase activity by flavonoids (1999) Arch. Pharm. Res., 22, pp. 309-312; Miksicek, R.J., Estrogenic flavonoids: Structural requirements for biological activity (1995) Proc. Soc. Exp. Biol. Med., 208, pp. 44-50; Liu, H.L., Jiang, W.B., Xie, M.X., Flavonoids: Recent advances as anticancer drugs (2010) Recent Pat. Anticancer Drug Discov., 5, pp. 152-164; Tan, A.R., Swain, S.M., Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy (2002) Seminars in Oncology, 29 (3 SUPPL. 11), pp. 77-85; Gerwick, W.H., Lopez, A., Van Duyne, G.D., Hormothamnione, a novel cytotoxic styrylchromone from the marine cyanophyte Hormothamnion enteromorphoides Grunow (1986) Tetrahedron Letters, 27 (18), pp. 1979-1982. , DOI 10.1016/S0040-4039(00)84426-3; Gerwik, W.H., 6-Desmethoxyhormothamnione, a new cytotoxic styrylchromone from the marine cryptophyte Chrysophaeum taylori (1989) J. Nat. Prod., 52, pp. 252-256; Lee, K.Y., Nam, D.H., Moon, C.S., Seo, S.H., Lee, J.Y., Lee, Y.S., Synthesis and anticancer activity of lavendustin A derivatives containing arylethenylchromone substituents (2006) European Journal of Medicinal Chemistry, 41 (8), pp. 991-996. , DOI 10.1016/j.ejmech.2006.04.008, PII S0223523406001541; Kumar, S.K., Hager, E., Pettit, C., Gurulingappa, H., Davidson, N.E., Khan, S.R., Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents (2003) Journal of Medicinal Chemistry, 46 (14), pp. 2813-2815. , DOI 10.1021/jm030213+; Huang, L., Wall, M.E., Wani, M.C., Navarro, H., Santisuk, T., Reutrakul, V., Seo, E.-K., Kinghorn, A.D., New compounds with DNA strand-scission activity from the combined leaf and stem of Uvaria hamiltonii (1998) Journal of Natural Products, 61 (4), pp. 446-450. , DOI 10.1021/np9703609; Ali, S., El-Rayes, B.F., Aranha, O., Sarkar, F.H., Philip, P.A., Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells (2005) Breast Cancer Research and Treatment, 90 (1), pp. 25-31. , DOI 10.1007/s10549-004-2179-x; Doble, B.W., Woodgett, J.R., GSK-3: Tricks of the trade for a multi-tasking kinase (2003) Journal of Cell Science, 116 (7), pp. 1175-1186. , DOI 10.1242/jcs.00384; Grimes, C.A., Jope, R.S., The multifaceted roles of glycogen synthase kinase 3? in cellular signaling (2001) Progress in Neurobiology, 65 (4), pp. 391-426. , DOI 10.1016/S0301-0082(01)00011-9, PII S0301008201000119; Luo, J., Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy (2009) Cancer Lett., 273, pp. 194-200; Hall, M., Peters, G., Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer (1996) Advances in Cancer Research, 68, pp. 67-108; Sutherland, R.L., Musgrove, E.A., Cyclin D1 and mammary carcinoma: New insights from transgenic mouse models (2002) Breast Cancer Research, 4 (1), pp. 14-17. , DOI 10.1186/bcr411; C�rdenas, M., Marder, M., Blank, V.C., Roguin, L.P., Antitumor activity of some natural flavonoids and synthetic derivatives on various human and murine cancer cell lines (2006) Bioorg. Med. Chem., 14, pp. 2966-2971; Navarini, A.L.F., Chiaradia, L.D., Mascarello, A., Fritzen, M., Nunes, R.J., Yunes, R.A., Creczynski-Pasa, T.B., Hydroxychalcones induce apoptosis in B16-F10 melanoma cells via GSH and ATP depletion (2009) Eur. J. Med. Chem., 44, pp. 1630-1637; Kerr, D.J., Kaye, S.B., Graham, J., Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester) (1986) Cancer Research, 46 (6), pp. 3142-3146; Valenti, P., Bisi, A., Rampa, A., Belluti, F., Gobbi, S., Zampiron, A., Carrara, M., Synthesis and biological activity of some rigid analogues of flavone-8- acetic acid (2000) Bioorganic and Medicinal Chemistry, 8 (1), pp. 239-246. , DOI 10.1016/S0968-0896(99)00282-5, PII S0968089699002825; Nuessler, V., Scheulen, M.E., Oberneder, R., Kriegmair, M., Goebel, K.J., Rathgeb, F., Wurst, W., Wilmanns, W., Phase i and pharmacokinetic study of the P-glycoprotein modulator dexniguldipine-HCl (1997) Eur. J. Med. Res., 2, pp. 55-61; Dimmock, J.R., Murthi Kandepu, N., Hetherington, M., Wilson Quail, J., Pugazhenthi, U., Sudom, A.M., Chamankhah, M., Balzarini, J., Cytotoxic activities of Mannich bases of chalcones and related compounds (1998) Journal of Medicinal Chemistry, 41 (7), pp. 1014-1026. , DOI 10.1021/jm970432t; Gul, H.I., Yerdelen, K.O., Gul, M., Das, U., Pandit, B., Li, P.-K., Secen, H., Sahin, F., Synthesis of 4?-hydroxy-3?-piperidinomethylchalcone derivatives and their cytotoxicity against PC-3 cell lines (2007) Archiv der Pharmazie, 340 (4), pp. 195-201. , DOI 10.1002/ardp.200600072; Schonberg, A., Sina, A., Khellin and allied compounds (1950) J. Am. Chem. Soc., 72, pp. 1611-1616; Dominguez, J.N., Leon, C., Rodrigues, J., De Dominguez, N.G., Gut, J., Rosenthal, P.J., Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivatives (2005) Journal of Medicinal Chemistry, 48 (10), pp. 3654-3658. , DOI 10.1021/jm058208o; Starkowsky, N.A., Addition of urea, thiourea and iodine to the natural benzopyrones of Ammi. Visnaga Linn. and Ammi. Majus Linn (1959) Egypt. J. Chem., 2, pp. 111-117; Schonberg, A., Badran, N., Starkovesky, N.A., Furochromones and coumarins VII. Degradation of visnagin, khellin and related substances, experiments with chromic acid and hydrogen peroxide, and synthesis of eugenitin (1953) J. Am. Chem. Soc., 75, pp. 4992-4995; El-Desoky, E.-S.I., Synthesis and reactions of some new allyl furobenzopyranone derivatives (2007) Journal of Heterocyclic Chemistry, 44 (6), pp. 1309-1315; Mahal, H., Rai, H., Venkatarama, K., Synthetical experiments in the chromone group. Part XVI. Chalkones and flavanones and their oxidation to flavones by means of selenium dioxide (1935) J. Chem. Soc., pp. 866-868; Geissman, T.A., Fukushima, D.K., Flavonones and gelated compounds (1948) J. Am. Chem. Soc., 70 M, pp. 1686-1689; Schonberg, A., Badran, N., Starkowsky, N.A., Furo-chromones and -coumarins. XII. Synthesis of fraxinol from bergapten and of baicalein from visnagin (1955) J. Am. Chem. Soc., 77, pp. 5390-5392; Schonberg, A., Mustafa, A., Aziz, G., Diels-Alder reaction. II. Experiments with 2-styrylchromones. on the nature of the dimer of 1,3-diphenylisobenzofuran (1954) J. Am. Chem. Soc., 76, pp. 4576-4577; Schonberg, A., Sina, A., On visnagin and khellin and related compounds. A simple synthesis of chromone (1950) J. Am. Chem. Soc., 72, pp. 3396-3399; Ragab, F.A., Abd-El-Latif, H.A., Synthesis, hypotensive and antispasmodic activities of certain aminomethylchromones (1992) Bull. Fac. Phar. Cairo Univ., 30, pp. 215-221; Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J.T., Boyd, M.R., New colorimetric cytotoxicity assay for anticancer-drug screening (1990) Journal of the National Cancer Institute, 82 (13), pp. 1107-1112; Dong, J., Peng, J., Zhang, H., Mondesire, W.H., Jian, W., Mills, G.B., Hung, M.-C., Meric-Bernstam, F., Role of glycogen synthase kinase 3? in rapamycin-mediated cell cycle regulation and chemosensitivity (2005) Cancer Research, 65 (5), pp. 1961-1972. , DOI 10.1158/0008-5472.CAN-04-2501; Altiok, N., Mezzadra, H., Patel, P., Koyuturk, M., Altiok, S., (2008) Breast Cancer Res. Treat., 109, pp. 315-323; Nada, A.A., Zayed, M.F., El Din, N.K., El-Saidi, M.M.T., Hefny, E., Photochemical reaction of phenanthrenequinone with some new aurones derived from khellin and visnagin (2002) Synthetic Communications, 32 (9), pp. 1293-1302. , DOI 10.1081/SCC-120003624; Ragab, F.A., Hassan, G.S., Yossef, H.A., Hashem, H.A., Synthesis of 6- and 9-alkylaminomethyl furoflavones as gastroprotective agents (2007) European Journal of Medicinal Chemistry, 42 (8), pp. 1117-1127. , DOI 10.1016/j.ejmech.2007.01.019, PII S022352340700058X; Lee, I., Boucher, Y., Jain, R.K., Nicotinamide can lower tumor interstitial fluid pressure: Mechanistic and therapeutic implications (1992) Cancer Res., 52, pp. 3237-3240
dcterms.source Scopus
dc.identifier.doi https://doi.org/10.1016/j.ejmech.2014.06.007
dc.identifier.doi PubMed ID 24937184
dc.Affiliation October University for modern sciences and Arts (MSA)


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search MSAR


Advanced Search

Browse

My Account